RPRX Royalty Pharma plc
Price Chart
Executive Summary
Two senior executives at Royalty Pharma sold a combined $4.2M in open-market sales over a 7-day window, including the CFO selling $3.48M. The sales occurred just after the company closed a $1.8B credit facility refinancing, which insiders would have been aware of. While the dollar amount is modest relative to the $31.1B market cap (0.01%), the CFO's sale is notable for its size and timing, though it may reflect routine portfolio rebalancing post-refinancing rather than a bearish signal.
Key Financial Metrics
Actionable Insight
The CFO's $3.48M sale is the largest insider transaction at RPRX in the past 30 days, but at 0.01% of market cap it is not material. The timing just after a credit facility refinancing suggests the sale may be liquidity-driven (e.g., tax planning, diversification) rather than informed selling. Monitor for any additional insider sales in the coming weeks, particularly if the CFO sells again at higher volumes. The 88% analyst bullish consensus and strong historical win rate (67% T+20) on this ticker suggest the cluster is not a sell signal.
Key Facts
- CFO Terrance Coyne sold 64,399 shares at $53.98 for $3.48M on 2026-05-26
- EVP Marshall Urist sold 13,700 shares at $52.75 for $722K on 2026-05-20
- Total insider sales of $4.2M represent ~0.01% of RPRX's $31.1B market cap
- Sales occurred 4 days after Royalty Pharma closed a $1.8B credit facility refinancing (8-K filed 2026-05-28)
- No open-market purchases were reported in the cluster window
Financial Impact
Total insider sales of $4.2M, or 0.01% of market cap — immaterial relative to company size
Risk Factors
- CFO selling $3.48M in a single transaction could indicate personal portfolio rebalancing, but if followed by additional C-suite sales, it may signal reduced conviction
- Insider sales are generally weak predictors of future returns per academic literature, especially when clustered near corporate events like refinancings
Market Snapshot
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-RPRX-1780001336204 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 28, 2026
12d ago
|
Insider Cluster
| $55.76 $55.87 | ▲ +0.20% | ▲ +2.72% | $54.86 (−1.61%) |
|
May 28, 2026
12d ago
|
8-K
| $55.76 $54.97 | ▼ −1.42% | ▼ −1.12% | $54.86 (−1.61%) |
|
May 22, 2026
19d ago
|
Insider Cluster
| $54.50 $55.18 | ▲ +1.25% | ▼ −0.41% | $54.86 (+0.66%) |
|
May 15, 2026
25d ago
|
Insider Cluster
| $52.07 $53.86 | ▲ +3.44% | ▲ +1.82% | $54.86 (+5.36%) |
|
May 14, 2026
26d ago
|
144
| $52.85 $54.50 | ▲ +3.12% | ▲ +2.16% | $54.86 (+3.80%) |
|
May 6, 2026
4w ago
|
8-K
| $50.72 $51.70 | ▲ +1.93% | ▲ +0.80% | $54.86 (+8.16%) |
|
Apr 17, 2026
7w ago
|
Press Release
| $50.00 $49.38 | ▼ −1.24% | ▼ −1.79% | $54.86 (+9.72%) |
|
Apr 15, 2026
7w ago
|
Press Release
| $48.48 $49.64 | ▲ +2.39% | ▲ +1.41% | $54.86 (+13.16%) |
|
Apr 10, 2026
8w ago
|
DEFA14A
| $48.43 $49.30 | ▲ +1.80% | ▼ −1.50% | $54.86 (+13.28%) |
|
Mar 30, 2026
10w ago
|
Press Release
| $46.37 $46.87 | ▲ +1.08% | ▼ −3.22% | $54.86 (+18.31%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access